Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812723 | 0.79 | GABRA1 (0.52) | SMN1; SMN2GABRA1LMNAGABRG2GABRB3 | |
| SCHEMBL6180997 | 0.77 | GABRA1 (0.50) | SMN1; SMN2GABRA1LMNAGABRG2GABRB3 | |
| SCHEMBL8750879 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2GABRA1LMNAGABRG2GABRB3 | |
| SCHEMBL28914676 | 0.75 | GABRA1 (0.48) | SMN1; SMN2GABRA1LMNAGABRG2GABRB3 | |
| SCHEMBL10037121 | 0.75 | GABRA1 (0.48) | SMN1; SMN2GABRA1LMNAGABRG2GABRB3 | |
| SCHEMBL28370355 | 0.75 | GABRA1 (0.48) | SMN1; SMN2GABRA1LMNAGABRG2GABRB3 | |
| SCHEMBL3116485 | 0.75 | GABRA1 (0.48) | SMN1; SMN2GABRA1LMNAGABRG2GABRB3 | |
| SCHEMBL3206761 | 0.75 | GABRA1 (0.48) | SMN1; SMN2GABRA1LMNAGABRG2GABRB3 | |
| SCHEMBL22767461 | 0.75 | GABRA1 (0.54) | SMN1; SMN2GABRA1LMNAGABRG2GABRB3 | |
| SCHEMBL8159500 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2GABRA1LMNAGABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305843-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | MILLENDO THERAPEUTICS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9546135-B2 | Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto | MILLENDO THERAPEUTICS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160090354-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090354-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | ATR, BAP1, ATRIP | SMN1; SMN2 3652/4885GABRA1 1296/4885LMNA 3482/4885 |
| US-20170305843-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | ATR, BAP1, ATRIP | SMN1; SMN2 3652/4885GABRA1 1296/4885LMNA 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.